Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017614 | 0.89 | HTT (0.62) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL5545852 | 0.85 | CYP2C19 (0.60) | MAPTHPGDMAPK1KDM4ECYP2C19 | |
| SCHEMBL9125307 | 0.83 | ALDH1A1 (0.65) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL18204569 | 0.83 | STAT3 (0.55) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL2217750 | 0.82 | MAPT (0.61) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL21765474 | 0.81 | SMN1; SMN2 (0.64) | MAPTHTTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL28251305 | 0.81 | ALDH1A1 (0.69) | MAPTHPGDKLK7ALDH1A1KDM4E | |
| SCHEMBL22089889 | 0.81 | KLK7 (0.63) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL28012910 | 0.80 | HTT (0.59) | MAPTHTTHPGDALOX12MAPK1 | |
| SCHEMBL588524 | 0.80 | HPGD (0.86) | MAPTHTTHPGDALOX12MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237921-A1 | METHOD FOR REMOVING ACETALDEHYDE | GE HEALTHCARE LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20170360943-A1 | METHOD FOR REMOVING ACETALDEHYDE | GE HEALTHCARE LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170360943-A1 | METHOD FOR REMOVING ACETALDEHYDE | GE HEALTHCARE LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9587001-B2 | Conjugated knottin mini-proteins containing non-natural amino acids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| WO-2016087653-A1 | METHOD OF REMOVING ACETALDEHYDE FROM RADIOACTIVE PHARMACEUTICALS | GE HEALTHCARE LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| CN-101107000-A | 3,6-bicyclolides | ENANTA PHARM INC (US) | 2008-01-16 | — | — | CN | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1732566-A2 | 6-AZAINDOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005097129-A2 | 6-AZAINDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360943-A1 | METHOD FOR REMOVING ACETALDEHYDE | ALDH2, ALDH1A1, ADH1A | MAPT 2218/4885HTT 842/4885HPGD 104/4885 |
| US-20200237921-A1 | METHOD FOR REMOVING ACETALDEHYDE | ALDH2, ALDH1A1, ADH1A | MAPT 2218/4885HTT 842/4885HPGD 104/4885 |
| US-20080064715-A1 | 6-Azaindole Compound | RELA, NFKBIA, GPR119 | MAPT 4532/4885HTT 3692/4885HPGD 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.